ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÎÒÃǵķþÎñ

×÷ΪÖйúµÚÈý·½¼ì²âÓëÈÏÖ¤·þÎñµÄ¿ªÍØÕߺÍÁìÏÈÕß £¬NG28ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²âΪȫÇò¿Í»§Ìṩһվʽ¼ìÑé¡¢²âÊÔ¡¢Ð£×¼¡¢ÈÏÖ¤¼°¼¼Êõ·þÎñ¡£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÐÒµ½â¾ö·½°¸

·þÎñÄÜÁ¦ÒÑÈ«ÃæÁýÕÖµ½·ÄÖ¯·þ×°¼°Ð¬°ü¡¢Ó¤Í¯Íæ¾ß¼°¼Ò¾ÓÉú»î¡¢µç×ÓµçÆ÷¡¢Ò½Ñ§½¡¿µ¡¢Ê³Æ·¼°Å©²úÎï……µÈÐÐÒµµÄ¹©Ó¦Á´ÉÏÏÂÓΡ£

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÌØÉ«·þÎñ

È«Ãæ±£ÕÏÆ·ÖÊÓëÄþ¾² £¬Íƶ¯ºÏ¹æÓ봴Р£¬ÕÃÏÔÆ·ÅƾºÕùÁ¦ £¬ÊµÏÖ¸ü¸ßÖÊÁ¿¡¢¸ü½¡¿µ¡¢¸üÄþ¾²¡¢¸üÂÌÉ«µÄ¿ÉÁ¬ÐøÉú³¤¡£

¼ÓÈëÎÒÃÇ
È˲ÅÕþ²ß
ÕÐÏÍÄÉÊ¿
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
È˲ÅÕþ²ß
±£ÕÏÔ±¹¤»ù±¾È¨ÒæÓ븣Àû£»Ìṩרҵ¼¼ÄÜÅàѵ £¬´Ù½øÔ±¹¤Éú³¤£»¿ªÕ¹¸»ºñ¶à²ÊµÄ»î¶¯ £¬Æ½ºâÔ±¹¤ÊÂÇéÓëÉú»î¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÕÐÏÍÄÉÊ¿
»¶Ó­¼ÓÈëÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿¼ì²â¸÷ÈËÍ¥ £¬ÎÒÃǽ«ÎªÄã´î½¨Ò»¸ö³äʵʩչ²ÅÆø £¬ÊµÏÖÖ°ÒµÀíÏëµÄÎę̀¡£
ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿
ÐÂÎÅ×ÊѶ

θ°©Ö¸ÄÏÍÆ¼ö¼ì²âµÄDZÔÚаеã--ÅãͬÕï¶ÏClaudin18.2ÃâÒß×黯

Ðû²¼Ê±¼ä£º2024-07-05 ä¯ÀÀ´ÎÊý£º5543

Claudin18.2(CLDN18.2)ÊÇClaudinÂѰ×ÖʼÒ×åµÄÒ»Ô± £¬Î»ÓÚϸ°ûĤÍâò £¬Ñо¿±íÃ÷Õý³£Çé¿öϽöµÍˮƽ±í´ïÓÚθճĤ·Ö»¯ÉÏÆ¤Ï¸°û £¬µ«ÔÚ²¡Àí״̬Ï £¬Claudin18.2ÔÚ¶àÖÖÖ×ÁöÖÐÓеıí´ïÏÔÖøÉϵ÷ £¬°üÂÞ80%µÄ賦µÀÏÙÁö¡¢60%µÄÒÈÏÙÖ×Áö £¬´ËÍ⻹¿É¼ûÓÚʳ¹Ü°©¡¢Âѳ²°©ºÍ·ÎÏÙ°©µÈ £¬ÊǾßÓÐDZÁ¦ÖÎÁư©Ö¢µÄÈÈÃŰеãÖ®Ò»¡£

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ͼƬÀ´Ô´£ºTher Adv Med Oncol 2024, Vol. 16: 1–18

 

Ò» Claudin18.2µÄ±í´ïºÍ¼ì²âÒªÁì


        Claudin¼Ò×åÖÁÉÙÓÐ27¸ö³ÉÔ± £¬¾ùÊǶ¨Î»ÓÚϸ°ûĤÍâòµÄ¿çĤÂÑ°× £¬Æä½á¹¹¾ßÓи߶ÈÒ»ÖÂÐÔ£º°üÂÞ4¸ö¿çÄ¤ÇøºÍ2¸ö°ûÍâ»· £¬ÆäÖÐNH2¶ËºÍCOOH¶ËλÓÚ°ûÄÚ £¬¾ßÓÐÁ½¸ö°ûÍâ»·¡£ÕâÖֽṹʹClaudin½ôÃÜÂѰ׼Ò×åÄܹ»ÓÐЧά³ÖÉÏÆ¤Ï¸°ûºÍÄÚÆ¤Ï¸°ûµÄ¼«ÐÔ £¬´Ó¶øÓÐЧµ÷¿ØÏ¸°ûÅÔͨ͸ÐԺ͵絼¡£

 

ClaudinÂѰ×ÊÇϸ°û¼ä½ôÃÜÁ¬½ÓµÄÖØÒª½á¹¹ÂÑ°× £¬ÆäÑÇÐÍClaudin18.2£¨CLDN18.2£©ÌØÒìÐÔ±í´ïÓÚ·Ö»¯µÄθÉÏÆ¤Ï¸°û £¬²¢ÔÚϸ°û¶ñ±ä¹ý³ÌÖб»¹ý¶È¼¤»î¡£Claudin18.2µÄÒì³£±í´ï»á¸Ä±ä½ôÃÜÁ¬½ÓÂѰ׵ÄÕý³£½á¹¹¼°¹¦Ð§ £¬´Ó¶øÊ¹Ï¸°û¼«ÐÔ¶ªÊ§ £¬ÔÊÐíÓªÑøÎïÖʼ°ÆäËû¶ÔÖ×Áöϸ°û´æ»îºÍÉú³¤µÄ±ØÐëÒò×ÓÀ©É¢ £¬ÔÚÖ×Áöϸ°ûµÄ×ªÒÆºÍÖ×Áöϸ°ûµÄÓªÑø¹©Ó¦ÖÐÆðµ½ÖØÒª×÷Óá£

 

Ŀǰ¼ì²âCLDN18.2±í´ï½ÏΪ³ÉÊìµÄÒªÁìÊÇÃâÒß×éÖ¯»¯Ñ§È¾É«£¨IHC£©¡£Claudin18.2µÄ¿¹ÌåÖÖÀàĿǰ¹úÄÚ»ñÅúµÄ¼ì²â¿¹Ìå20¼Ò+ £¬´ó¶àÊý¹ØÓÚClaudin-18.2ÔÚθ°©Öбí´ïÂʵı¨µÀÊÇ»ùÓÚʹÓÃÓëClaudin-18.1ºÍClaudin-18.2ÔÚC¶ËÅäºÏ±íλµÄ¿¹Ìå½øÐÐÃâÒßȾɫµÄ½á¹û¡£Ò»°ã½ÓÄÉȾɫǿ¶È¼°ÑôÐÔϸ°ûÂÊ×÷ΪCLDN18.2±í´ïµÄ¶¨Á¿·ÖÎöÖ¸±ê £¬È¾É«Ç¿¶È¿É·ÖΪ0£¨Ï¸°ûĤ»òϸ°ûÖÊÎÞ·´Ó³£©¡¢1+£¨Ï¸°ûĤ»òϸ°ûÖÊÈõ·´Ó³ÐÔ£©¡¢2+£¨Ï¸°ûĤ»òϸ°ûÖÊÖз´Ó³£©¡¢3+£¨Ï¸°ûĤ»òϸ°ûÖÊÇ¿·´Ó³ÐÔ£© £¬Ï±í»ã×ܽüÄêÀ´ÎÄÏ×±¨µÀÏà¹ØÑо¿¼°CLDN18.2ÑôÐÔÅжÁÒªÁ죺

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

ͼƬÀ´Ô´£ºÍøÂç

 

¶þ Ö¸ÄÏÍÆ¼ö


1 ±í¸ñÍÆ¼öÆ·¼¶ÓÉ2023°æµÄ¢ó¼¶ÍƼö¸ÄΪ2024°æ¢ò¼¶ÍƼö

 

ÄϹ¬(28NG¡¤¹ú¼Ê)¹Ù·½ÍøÕ¾-ÏàÐÅÆ·ÅÆÁ¦Á¿

2 ×¢ÊͲ¿ÃÅ

Claudin 18.2ͨ¹ýÃâÒß×黯Ðмì²â £¬Ä¿Ç°ÑôÐÔÅжÁ³ß¶È½öÀ´×ÔÁÙ´²ÊÔÑé¡£Claudin 18.2ÑôÐÔÓÉÖ×Áöϸ°ûÍêÕû¡¢»ùµ×Íâ²à»òÍâ²àĤȾɫµÄÇ¿¶È £¬ÒÔ¼°Ö×Áöϸ°ûĤ×ÅÉ«ËùÕ¼°Ù·Ö±ÈÁ½¸ö·½Ãæ¾ö¶¨ £¬µ«²îÒìµÄÁÙ´²Ñо¿½ÓÄɲîÒìµÄÅжÁ³ß¶È¡£

Èý ÄϹ¬28NGÏàÐÅÆ·ÅÆÁ¦Á¿²¡ÀíÏîÄ¿ÉÏÐÂ

ÎÒÃÇÔËÓÃÃâÒß×黯 £¬ÍêÃÀÚ¹ÊÍClaudin 18.2±í´ï £¬½ô¸úÖ¸ÄϸüР£¬¸üÈ«ÃæÖúÁ¦ÁÙ´²¡£


1 ²úÎï¼ò½é

ÅãͬÕï¶ÏClaudin 18.2ÃâÒß×黯 £¬¶ÔÓÚClaudin 18.2±í´ïÑôÐÔµÄθ°©»òÆäËûʵÌåÁö»¼Õß £¬Ô½ÔçÈ·¶¨Claudin 18.2ÂѰױí´ï״̬ £¬°ÐÏòÖÎÁƲÅÓпÉÄÜÔ½´ó»ñÒæ¡£

 

2 ¼ì²âÒªÁì

ÃâÒß×éÖ¯»¯Ñ§È¾É«

ÏÔ΢¾µ¾µ¼ì

 

3 Ñù±¾ÀàÐÍ

×éÖ¯£¨À¯¿é¡¢·ÀÍÑ°×Æ¬»òÐÂÏÊ×éÖ¯£©

 

4 ¼ì²âÖÜÆÚ

4¸öÊÂÇéÈÕ¡£

 

5 ÊÊÓÃÈËȺ

θ°©»¼Õß

ʵÌåÁö»¼Õß

 

ËÄ ²Î¿¼ÎÄÏ×

[1] Günzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev. 2013;93(2):525-569.

[2] Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. 

[3] Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141.

[4] 2024 CSCOθ°©ÕïÁÆÖ¸ÄÏ

ÍøÕ¾µØÍ¼